Search
for
Sort by
Research 30 of 353
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
- Network pharmacology and molecular docking analysis on potential molecular targets and mechanism of action of BRAF inhibitors for application in wound healing
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
- Melanotic pigmentation in excisional scar of melanoma patient who received BRAF and MEK inhibitors
- 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
- Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
- Abstract 1677: Epithelial hyperplasia induced by a selective B-Raf inhibitor, WYE-130600
- 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
- Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
- Alopecia due to chemotherapeutics, hedgehog inhibitors, targeted antibody therapies and immune checkpoint inhibitors
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- Cutaneous toxicities of new treatments for melanoma
- The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma
- Management of Dermatologic Toxicities
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Diseases of the Canine Prostate Gland
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- The Influence of Flightless I: Regeneration versus Wound Healing
- Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
- RASopathic Skin Eruptions during Vemurafenib Therapy
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
- Is knowledge about the genetic and epigenetic alterations in melanoma a basis for targeted therapy?
- Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma
- Management of Toxicities of Targeted Therapies
- Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
- Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma